TVAX Biomedical
Lenexa
About TVAX Biomedical
TVAX Biomedical is a clinical stage development company advancing its targeted cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. TVAX Immunotherapy is a unique personalized combination of cancer cell vaccination and “killer” T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. A key distinction between TVAX and other cancer immunotherapy companies is that TVI uses its patented approach to combine both cancer vaccination and activated “killer” T cell treatment. While each of these separate approaches has demonstrated therapeutic potential, neither has demonstrated the efficacy to be a viable standalone treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $14.7M
- Last round: Grant (Oct 2022)
- Website: tvaxbiomedical.com
- Phone: (913) 492-2221
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tvax-biomedical-76333 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.